<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02584075</url>
  </required_header>
  <id_info>
    <org_study_id>Exen100</org_study_id>
    <nct_id>NCT02584075</nct_id>
  </id_info>
  <brief_title>Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <brief_summary>
    <textblock>
      Type 2 diabetes mellitus (T2DM) is an important risk factor of cardio-cerebral vascular
      disease such as coronary heart disease. GLP-1 is a kind of incretin secreted by the L-cell
      located in Ileum. It acts as an incretin hormone by protentiating glucose-stimulated insulin
      release. Recent studies reported that GLP-1 RA can protect the vascular endothelial and
      prevent vascular from atherosclerosis. Investigators design this study to investigate
      exenatide's effect on the improvement of the coronary endothelial function by evaluating
      endothelium dependent diastolic function and testing the vascular endothelial active
      substance and related inflammatory factors.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary endothelial function</measure>
    <time_frame>the change of coronary endothelial function(baseline, 12 weeks)</time_frame>
    <description>the change of coronary flow velocity reserve (CFVR)(baseline, 12 weeks)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the changes of fasting plasma glucose (FPG)</measure>
    <time_frame>the changes of fasting plasma glucose (FPG)(baseline, 12 weeks)</time_frame>
    <description>the changes of fasting plasma glucose (FPG) (baseline, 12 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the changes of HbA1C</measure>
    <time_frame>the changes of HbA1C(baseline, 12 weeks)</time_frame>
    <description>the changes of HbA1C (baseline, 12 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the changes of fasting serum insulin (FINS)</measure>
    <time_frame>the changes of fasting serum insulin (FINS) (baseline, 12 weeks)</time_frame>
    <description>the changes of fasting serum insulin (FINS) (baseline, 12 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the changes of IL-1B</measure>
    <time_frame>the changes of IL-1B (baseline, 12 weeks)</time_frame>
    <description>the changes of IL-1B (baseline, 12 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the changes of IL-6</measure>
    <time_frame>the changes of IL-6 (baseline, 12 weeks)</time_frame>
    <description>the changes of IL-6 (baseline, 12 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the changes of TNF-α</measure>
    <time_frame>the changes of TNF-α(baseline, 12 weeks)</time_frame>
    <description>the changes of TNF-α(baseline, 12 weeks)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Coronary Endothelial Function</condition>
  <arm_group>
    <arm_group_label>Lifestyle intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Byetta (Exenatide)</intervention_name>
    <description>Exenatide treatment: 5 µg twice/day subcutaneous injection for 4 weeks, 10 µg twice/day subcutaneous injection for 8 weeks.</description>
    <arm_group_label>Lifestyle intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucophage ( Metformin Hydrochloride)</intervention_name>
    <description>Metformin 500mg Tid</description>
    <arm_group_label>Lifestyle intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females or males, and aged 20 to 65 years

          -  Newly diagnose type 2 diabetes mellitus with BMI&gt;25kg/m2.

          -  HbA1C&gt;8%.

        Exclusion Criteria:

          -  Type 1 diabetes mellitus, diabetic ketoacidosis, diabetic hyperosmolar coma.

          -  Hepatic insufficiency (ALT or AST&gt; 1.5*ULN).

          -  Renal insufficiency [Creatinine clearance rate (Ccr)]&lt;60ml/min estimated from MDRD
             equation).

          -  Thyroid disease

          -  Use of any anti-diabetic, anti-hypertension or anti-dyslipidemia drugs.

          -  Pregnant or lactating woman.

          -  Severe anemia.

          -  Acute myocardial infarction or stoke.

          -  Other conditions at investigator's discretion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>October 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2015</study_first_posted>
  <last_update_submitted>October 21, 2015</last_update_submitted>
  <last_update_submitted_qc>October 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Guang Wang</investigator_full_name>
    <investigator_title>Director,Head of Endocrinology,Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

